Impact of Intraoperative Cell Salvage

Last updated: May 4, 2025
Sponsor: Icahn School of Medicine at Mount Sinai
Overall Status: Active - Recruiting

Phase

N/A

Condition

Anemia

Treatment

Intraoperative cellular salvage

Clinical Study ID

NCT06240117
STUDY-23-01380
  • Ages > 18
  • Female

Study Summary

Patients presenting for elective cesarean section will be screened for pre-procedural anemia. If the potential subject meets the selection criteria they will be presented with the option of participating in the study. Once consented the participant is randomized by envelope. The two groups studied are: standard of care with intraoperative cell salvage and standard of care without cell salvage. If the participant is randomized to the cell salvage group, the study team will notify the anesthesia and obstetrics (OB) team and will set up the cell salvage system per protocol. The primary end point is to determine the difference in postoperative hemoglobin at 48hrs, need and quantity of allogeneic blood product transfusion, length of hospital stay between the two groups studied. The secondary endpoints Investigate the impact of using IOCS on clinical parameters associated with maternal postpartum stability and well being and include estimation of blood loss, need for pressors, uterotonics, return to the operating room, uterine compression devices, ICU admission, postoperative blood product transfusion, IV iron supplementation, blood chemistry, coagulation parameters, oliguria, diagnosis of acute kidney injury, postoperative dialysis, acute respiratory distress syndrome, pulmonary edema, pneumonia, deep vein thrombosis, pulmonary embolism, oxygen requirement, new arrythmias APGAR scores, anemia fatigue scale at 24hr and 48 hrs, OBSQOR10 score 24 hours and 48 hours postpartum and 6 week postpartum EPDS score.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Women aged 18-55 years.

  • Presenting for elective cesarean section.

  • With hemoglobin less or equal to 11 mg/dL.

  • Able to provide informed written consent.

Exclusion

Exclusion criteria:

  • Refusal of blood product administration.

  • Refusal of intraoperative blood salvage.

Study Design

Total Participants: 12
Treatment Group(s): 1
Primary Treatment: Intraoperative cellular salvage
Phase:
Study Start date:
March 11, 2024
Estimated Completion Date:
May 31, 2026

Connect with a study center

  • The Mount Sinai Hospital

    New York, New York 10029
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.